TABLE 2.
Study n Length of Follow-up Quality | LHRH Dose | LHRH Frequency | LHRH Duration | LHRH Descent, % | Placebo Descent, % |
---|---|---|---|---|---|
Statistical Significance | |||||
Olsen et al 199215 | 400 µg | 3 times daily | 4 wk | 9.7 | 1.6 |
n = 123 | |||||
4 wk | |||||
Fair | |||||
P = .12 (95% CI: 0.1%–16.6%) | |||||
Christiansen et al 198814 | 200 µg | 3 times daily | 4 wk | 9 (bilateral cryptorchidism) | 0 (bilateral cryptorchidism) |
n = 220 | 0 (unilateral cryptorchidism) | 0 (unilateral cryptorchidism) | |||
4 wk | |||||
Fair | |||||
NS | |||||
De Muinck Keizer-Schrama and Hazebroek et al 1986–19879–11 | 200 µg | 3 times daily | 4 wk | 9.0 | 8.0 |
n = 237 | |||||
8 wk | |||||
Poor | |||||
NR | |||||
Hagberg and Westphal, 198212 | 100 µg | 3 times daily | 28 d | 62.0 | 3.0 |
n = 50 | |||||
4 wk | |||||
Poor | |||||
NR | |||||
Karpe et al 198313 | 100 µg | 6 times daily | 28 d | 20.0 | 12.0 |
n = 50 | |||||
6 mo | |||||
Poor | |||||
NR | |||||
Wit et al 198616 | 400 µg | 3 times daily | 28 d | 37 | 18 |
n = 49 | |||||
8 wk | |||||
Poor | |||||
NR |
CI, confidence interval; LHRH, luteinizing-hormone-releasing hormone; NR, not reported; NS, not significant.